Medicus Eyes SPAC Merger for SkinJect Unit

Medicus Pharma signed a nonbinding letter of intent to spin off SkinJect through a SPAC transaction valuing the subsidiary at $135 million.

Updated on Nov. 11, 2026 in Biotech

Medicus Eyes SPAC Merger for SkinJect Unit

Philadelphia-based Medicus Pharma Ltd., listed on Nasdaq under MDCX, signed a nonbinding letter of intent with an unidentified special purpose acquisition company to combine its SkinJect subsidiary with the SPAC. The preliminary pre-money valuation of SkinJect is $135 million, and the transaction includes concurrent equity financing.

Why it matters

The structure would let SkinJect fund its clinical development as a separately listed business while Medicus keeps majority economic and voting control. Because most provisions remain nonbinding, the terms could change before any definitive agreement is reached.

The $135 million pre-money valuation is a preliminary negotiating figure from a nonbinding letter of intent, and the SPAC would acquire 100% of SkinJect in exchange for newly issued common shares. The unidentified SPAC, final pricing and financing amounts remain unresolved pending definitive agreements.

The players

Medicus Pharma Ltd.

A Philadelphia-based biotechnology company listed on Nasdaq under the ticker MDCX that developed the SkinJect subsidiary and intends to keep majority control of the resulting business.

The details

Under the proposed structure, the SPAC would acquire all of SkinJect in exchange for new shares of the combined company, with concurrent equity financing supporting SkinJect's clinical development. Completion would require satisfactory due diligence, negotiated definitive agreements, successful equity financing and compliance with a minimum-cash condition.

Timeline

  1. November 11, 2026: Medicus announced the nonbinding letter of intent for the proposed SkinJect SPAC merger.

  2. First half of 2027: Medicus anticipates completing the business combination.

Market Landscape

Biotech companies increasingly use SPAC mergers to separately fund and list clinical-stage subsidiaries while keeping control of the asset. Medicus's proposed SkinJect transaction follows that pattern, using a SPAC to finance clinical development outside the parent company's balance sheet.

Shareholders of Medicus would hold a stake in a combined company whose SkinJect unit is separately funded, but final share terms are not yet set. Investors should watch for definitive agreements, the identity of the SPAC and any financing terms before the first half of 2027.

The takeaway

The SPAC structure lets Medicus raise money for SkinJect while keeping control, but the deal is preliminary and its terms could shift before a binding agreement. Readers should treat the $135 million valuation as an opening figure rather than a settled price.

Further reading

For more on the sector, browse Biotech coverage.

Source note: This article includes information reported by MyChesCo.